A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The phase 3b open-label, randomized controlled trial showed that patients treated with tirzepatide vs semaglutide lost an average of 20.2% vs 13.7% of their baseline weight over the 72 weeks.

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

This translated to a loss of 22.8 kg in the tirzepatide-treated patients versus 15.0 kg in those who received semaglutide. David Horner, MD, PhD (Copenhagen University Hospital, Denmark), who wasn’t ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...